Page 19 - EASL Recommendations on Treatment of Hepatitis C 2015 - Summary
P. 19
Table 4E. Drug-drug interactions between Table 4F. Drug-drug interactions between
HCV DAAs and cardiovascular drugs. HCV DAAs and immunosuppressants.
SIM DCV SOF SOF/ 3D SIM DCV SOF SOF/ 3D
LDV LDV
•
Antiplatelet Amiodarone ••• • • Azathioprine •••••
and antico- Antiarrythmics Digoxin •
Flecainide ••• • • Cyclosporine •••••
agulants Vernakalant •
Clopidogrel ••• • • Etanercept •••••
Dabigatran •
Warfarin ••• • • Everolimus •••••
Atenolol •
Bisoprolol ••• • • Mycophenolate • • • • •
Propranolol •
Amlodipine ••• • Sirolimus •••••
Diltiazem
Nifedipine ••• • Tacrolimus •••••
Aliskiren
Beta Candesartan ••• • SIM, simeprevir; DCV, daclatasvir; SOF, sofosbuvir; SOF/LDV,
blockers Doxazosin sofosbuvir plus ledipasvir; 3D, ritonavir-boosted paritaprevir,
••• • plus ombitasvir and dasabuvir.
Enalapril Colour legend. Green: No clinically significant interaction
••• • expected. Amber: Potential interaction which may require a
dosage adjustment, altered timing of administration or additional
Calcium ••• • monitoring. Red: These drugs should not be co-administered.
channel
blockers ••• • • o Some drugs may require dose modifications
••• • • dependent on hepatic function. Please refer to the
Hypertension ••• • • product label for individual drugs for dosing advice.
and heart ••• • •
o The symbol (green, amber, red) used to rank the
failure agents ••• • • clinical significance of the drug interaction is based on
www.hep-druginteractions.org
••• • • (University of Liverpool). For additional drug-drug
interactions and for a more extensive range of drugs,
SIM, simeprevir; DCV, daclatasvir; SOF, sofosbuvir; SOF/LDV, detailed pharmacokinetic interaction data and dosage
sofosbuvir plus ledipasvir; 3D, ritonavir-boosted paritaprevir, adjustments, refer to the above-mentioned website.
plus ombitasvir and dasabuvir.
Colour legend. Green: No clinically significant interaction
expected. Amber: Potential interaction which may require a
dosage adjustment, altered timing of administration or additional
monitoring. Red: These drugs should not be co-administered.
o Some drugs may require dose modifications
dependent on hepatic function. Please refer to the
product label for individual drugs for dosing advice.
o The symbol (green, amber, red) used to rank the
clinical significance of the drug interaction is based on
www.hep-druginteractions.org
(University of Liverpool). For additional drug-drug
interactions and for a more extensive range of drugs,
detailed pharmacokinetic interaction data and dosage
adjustments, refer to the above-mentioned website.
18
HCV DAAs and cardiovascular drugs. HCV DAAs and immunosuppressants.
SIM DCV SOF SOF/ 3D SIM DCV SOF SOF/ 3D
LDV LDV
•
Antiplatelet Amiodarone ••• • • Azathioprine •••••
and antico- Antiarrythmics Digoxin •
Flecainide ••• • • Cyclosporine •••••
agulants Vernakalant •
Clopidogrel ••• • • Etanercept •••••
Dabigatran •
Warfarin ••• • • Everolimus •••••
Atenolol •
Bisoprolol ••• • • Mycophenolate • • • • •
Propranolol •
Amlodipine ••• • Sirolimus •••••
Diltiazem
Nifedipine ••• • Tacrolimus •••••
Aliskiren
Beta Candesartan ••• • SIM, simeprevir; DCV, daclatasvir; SOF, sofosbuvir; SOF/LDV,
blockers Doxazosin sofosbuvir plus ledipasvir; 3D, ritonavir-boosted paritaprevir,
••• • plus ombitasvir and dasabuvir.
Enalapril Colour legend. Green: No clinically significant interaction
••• • expected. Amber: Potential interaction which may require a
dosage adjustment, altered timing of administration or additional
Calcium ••• • monitoring. Red: These drugs should not be co-administered.
channel
blockers ••• • • o Some drugs may require dose modifications
••• • • dependent on hepatic function. Please refer to the
Hypertension ••• • • product label for individual drugs for dosing advice.
and heart ••• • •
o The symbol (green, amber, red) used to rank the
failure agents ••• • • clinical significance of the drug interaction is based on
www.hep-druginteractions.org
••• • • (University of Liverpool). For additional drug-drug
interactions and for a more extensive range of drugs,
SIM, simeprevir; DCV, daclatasvir; SOF, sofosbuvir; SOF/LDV, detailed pharmacokinetic interaction data and dosage
sofosbuvir plus ledipasvir; 3D, ritonavir-boosted paritaprevir, adjustments, refer to the above-mentioned website.
plus ombitasvir and dasabuvir.
Colour legend. Green: No clinically significant interaction
expected. Amber: Potential interaction which may require a
dosage adjustment, altered timing of administration or additional
monitoring. Red: These drugs should not be co-administered.
o Some drugs may require dose modifications
dependent on hepatic function. Please refer to the
product label for individual drugs for dosing advice.
o The symbol (green, amber, red) used to rank the
clinical significance of the drug interaction is based on
www.hep-druginteractions.org
(University of Liverpool). For additional drug-drug
interactions and for a more extensive range of drugs,
detailed pharmacokinetic interaction data and dosage
adjustments, refer to the above-mentioned website.
18
